Novartis Wants More Time To Answer EMA’s Zolgensma Questions

 
• By Maureen Kenny

Novartis unit AveXis is one of several companies seeking extra time to address questions the European Medicines Agency has regarding their marketing applications. The company says it could get a decision on whether the product should be approved in the EU by year-end.

Many clocks in a vending machine to illustrate the importance and fleeting nature of time and the desire to buy more and make a moment last longer - Illustration
Extra time is sometimes needed to answer EMA's questions • Source: Shutterstock

More from Europe

More from Geography